ILMN · earnings call history
Illumina Q1 FY26 — Strong Clinical Growth and NovaSeq X Demand Drive Raised Outlook
Read the briefIllumina Q4 FY25 — Clinical Consumables Drive Strong Performance
Read the briefIllumina Q3 FY25 — Strong Clinical Growth and NovaSeq X Transition
Read the briefBrowse all US companies on the earnings-call register.